Everest Medicines Achieves Preclinical Milestone for mRNA Rabies Vaccine
China-based Everest Medicines (HKG: 1952) has announced that the company has achieved the preclinical proof-of-concept...
Alternative Bio Completes $15M Seed Round to Advance Cancer Therapeutics
Singapore-based Alternative Bio Inc. has announced the completion of a seed financing round at USD...
Shanghai Pharmaceuticals Partners with HKSTP for Biomedicine Cultivation Program
Shanghai Pharmaceuticals (HKG: 2607, SHA: 601607), Shanghai Biomedical Frontier Industry Innovation Center Co., Ltd, and...
111 Inc. Begins Online Sales of Pfizer’s Paxlovid in China
China-based online pharmacy 111 Inc. (NASDAQ: YI) reportedly initiated online retail sales of Pfizer Inc.’s...
Biosion and ImmunoGen Collaborate on Cancer ADCs
China-based Biosion Inc. announced an exploratory research collaboration to create antibody-drug conjugates (ADCs) for the...
Abcam and Wuxi Diagnostics Expand Partnership into Companion Diagnostics
UK-headquartered Abcam plc. and China-based Wuxi Diagnostics have expanded their partnership to dive deep into...
Henlius Biotech Partners with Medilink for Global ADC Development
Shanghai Henlius Biotech Inc. (HKG: 2696) announced a strategic partnership with Suzhou-based Medilink Therapeutics, obtaining...
Ascentage Pharma’s APG-2575 Shows Promising Results in Global Phase II Study
Suzhou-based Ascentage Pharma (HKG: 6855) unveiled preliminary data from the global Phase II clinical study...
Lifetech Scientific Completes Enrollment for IBS Coronary Stent Phase II Study
China-based Lifetech Scientific Corporation (HKG: 1302) announced that all patients have been enrolled in a...
China’s COVID-19 Vaccination Second Booster Shot Plan Released
The National Health Commission website indicates that the COVID-19 Joint Prevention and Control Mechanism of...
ImmuneOnco’s IMM2520 Receives FDA Clinical Trial Approval
ImmuneOnco Biopharmaceuticals (Shanghai) Co., Ltd announced receiving clinical trial approval from the US FDA for...
Jiangsu Recbio’s COVID-19 Vaccine ReCOV Shows Superiority in Phase II Trial
China-based vaccine maker Jiangsu Recbio Technology Co., Ltd (HKG: 2179) announced the positive results of...
Treadwell Therapeutics Presents PLK4 Inhibitor Data at ASH Annual Meeting
China-based Treadwell Therapeutics presented results of the company’s CFI-400945 program, a first-in-class inhibitor of Polo-like...
Cryofocus Biotechnology’s RDN System Gains FDA Breakthrough Therapy Designation
Shanghai-based cryoablation treatment specialist Cryofocus Medtech (Shanghai) Co., Ltd’s in-house developed Cryofocus RDN System, a...
Beijing Releases COVID-19 Infection Drug List to Address Stocking Issues
The Beijing Municipal Health Commission formulated and released the “COVID-19 infection drug list” (first edition),...
Cutia Therapeutic Plans IPO on Hong Kong Stock Exchange
China-based dermatology specialist Cutia Therapeutic announced plans to make an initial public offering (IPO) to...
China’s State Council Boosts Internet Medical Services Amid COVID-19
The State Council released a notification in relation to the COVID-19 pandemic, seeking to ramp...
Asieris Pharmaceuticals Enrolls First Patient in Phase II Study for APL-1202
China-based Asieris Pharmaceuticals (SHA: 688176) announced the first patient enrollment in a Phase II clinical...
Jiangsu Yahong Administers First Dose of Hexvix in Hainan Pilot Zone
China-based urogenital cancer specialist Jiangsu Yahong Meditech Co., Ltd (Asieris, SHA: 688176) announced the first...
Ascletis Pharma Announces Positive Phase I Results for ASC10 in COVID-19 Treatment
China-based Ascletis Pharma Inc., (HKG: 1672) announced the positive topline results from its Phase I...